The US Food and Drug Administration (FDA) published the internal checklists its staff reference when reviewing drug and biologics applications to determine whether the submission is complete, or ...
When a new drug application (NDA) or biologics license application (BLA) is deemed incomplete by the US Food and Drug Administration (FDA), the agency can decide not to review the application. So when ...
Zacks Investment Research on MSN
FDA accepts IBRX's filing seeking expanded use of bladder cancer therapy
Shares of ImmunityBio IBRX were up 3% in after-market trading yesterday after the company announced that the FDA accepted its regulatory filing seeking to expand the use of its sole marketed drug, ...
MIRA trial data demonstrated a 43% response with 120mg SLK, and a 29 ppt delta vs placebo (p < 0.001) at week 12. VELA-1 met all primary and key secondary endpoints with statistical significance ...
WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization and development of ...
President and CEO Lynn Seely outlined the company’s clinical development priorities, regulatory strategy and manufacturing ...
Sanofi SNY announced that the FDA has accepted its regulatory filing seeking approval for its investigational BTK inhibitor tolebrutinib to treat non-relapsing secondary progressive multiple sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results